RTW Investments LP Has $25.01 Million Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)

RTW Investments LP lifted its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 82.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,065,010 shares of the company's stock after acquiring an additional 931,223 shares during the period. RTW Investments LP owned approximately 3.02% of Replimune Group worth $25,007,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. JPMorgan Chase & Co. boosted its holdings in Replimune Group by 3.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 249,349 shares of the company's stock valued at $2,733,000 after purchasing an additional 8,074 shares during the period. SG Americas Securities LLC increased its holdings in shares of Replimune Group by 14.7% during the fourth quarter. SG Americas Securities LLC now owns 26,291 shares of the company's stock worth $318,000 after purchasing an additional 3,374 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Replimune Group by 24.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company's stock valued at $198,000 after buying an additional 3,177 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Replimune Group by 8.3% in the fourth quarter. Rhumbline Advisers now owns 95,465 shares of the company's stock valued at $1,156,000 after buying an additional 7,317 shares during the period. Finally, New York State Common Retirement Fund grew its position in Replimune Group by 260.8% during the fourth quarter. New York State Common Retirement Fund now owns 43,204 shares of the company's stock worth $523,000 after buying an additional 31,231 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. BMO Capital Markets increased their price target on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. JPMorgan Chase & Co. increased their price target on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Finally, HC Wainwright increased their price target on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $19.43.

Replimune Group Price Performance

Shares of REPL stock traded up $0.35 on Monday, hitting $8.20. 1,001,257 shares of the company's stock were exchanged, compared to its average volume of 904,628. The company has a 50 day moving average of $8.87 and a 200 day moving average of $11.30. The stock has a market cap of $631.52 million, a P/E ratio of -2.67 and a beta of 0.68. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. Replimune Group, Inc. has a 12 month low of $4.92 and a 12 month high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). On average, equities research analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.